Vaxcyte (PCVX) vs Twist Bioscience (TWST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Twist Bioscience (TWST) has outperformed Vaxcyte (PCVX) over the past year, gaining 400.2% versus a gain of 59.9%. Over five years, PCVX leads with a +174.3% price change compared with +38.0% for TWST. Twist Bioscience is the larger company by market cap ($10.32 billion vs $9.96 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PCVX | TWST |
|---|---|---|
| Share price | $66.96 | $155.65 |
| Market cap | $9.96B | $10.32B |
| 1-day change | +0.39% | -6.78% |
| YTD return | +45.12% | +390.70% |
| 1-year return | +59.92% | +400.16% |
| 5-year return | +174.31% | +37.99% |
| EPS (TTM) | $-7.66 | $-2.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $376.57M |
| Revenue growth (YoY) | — | +20.32% |
| Net income (latest FY) | $-766.63M | $-77.67M |
| Gross margin | — | 50.72% |
| Operating margin | — | -36.18% |
| Net margin | — | -20.63% |
| 52-week high | $90.75 | $219.71 |
| 52-week low | $39.87 | $23.30 |
| Distance from 52-week high | -26.21% | -29.16% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +65.59% | -14.07% |
| Average volume | 1.50M | 1.93M |
| Shares outstanding | 148.81M | 66.30M |
| Employees | 507 | 979 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TWST has outperformed PCVX by 340.2 percentage points over the past year.
About Vaxcyte
PCVX stock →Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 507 employees
About Twist Bioscience
TWST stock →Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 979 employees
PCVX vs TWST FAQ
Which is bigger, Vaxcyte or Twist Bioscience?
Twist Bioscience (TWST) is larger, with a market capitalization of $10.32B compared with $9.96B for Vaxcyte (PCVX).
Which stock has performed better over the past year, PCVX or TWST?
TWST returned +400.16% over the past 12 months, compared with +59.92% for PCVX (price return, excluding dividends). Past performance does not predict future results.
Are Vaxcyte and Twist Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.